The question
LL-37 has been studied in people, including a larger trial of a topical preparation for difficult-to-heal venous leg ulcers. That trial did not establish a significant healing advantage across its full study population. A favorable exploratory subgroup finding should be understood within that overall result. Original HEAL LL-37 report.
What the trial tested
The phase IIb study was randomized, double-blind and placebo-controlled. Of 149 randomized patients, 148 received treatment. It compared two topical LL-37 concentrations with placebo, alongside compression therapy. The primary endpoint concerned confirmed complete wound closure. Overall efficacy analyses found no significant improvement over placebo. Study methods and results.
The formulation and accompanying care are part of the experiment. This was not a comparison of injected LL-37 with no treatment, nor a general test of immune health. A clinical result cannot be transferred to those settings merely because the compound name is the same.
Where the encouraging subgroup came from
The authors' post hoc analysis found favorable results on several measures in patients with larger wounds and called for a study designed to evaluate that possibility. “Post hoc” means this analysis was conducted after the fact rather than serving as the trial's primary test. Trial report.
Such a finding can generate a useful hypothesis. It does not automatically identify a group in which treatment is established. Looking across several subgroups and outcomes creates more opportunities to find a promising pattern, so a new, planned comparison is especially valuable.
A reader can hold both findings at once: the full-population comparison was negative, and a narrower question may deserve additional research. Neither needs to be hidden to make the research story interesting.
Wound closure is not the same as every sign of improvement
A wound becoming smaller, closing completely, closing sooner and remaining closed are related but distinct outcomes. An article should name the endpoint before presenting a benefit. Otherwise, a percentage reduction in area can be mistaken for the percentage of people whose wounds healed.
The same discipline applies to laboratory descriptions such as antimicrobial activity. A biological property can motivate an experiment, but patient benefit must be assessed in the relevant clinical setting. It cannot be inferred from the category label alone.
Safety and US context
FDA's compounding safety page flags insufficient information and potential immune-reaction concerns for LL-37. It also notes adverse reproductive and tumor-related findings in nonclinical research; these do not quantify human risk. FDA assessment, checked September 26, 2026. Compounded products are not FDA-approved. FDA explanation.
This article does not establish an approved LL-37 therapy. To evaluate a new claim, identify the exact preparation, route, patient group and planned outcome before looking at selected positive results. For related evidence literacy, see BPC-157 human research and what peptides are.
Sources & further reading
Research context last reviewed September 26, 2026. Last updated October 6, 2026. Educational reading, not individual medical advice. How this article was prepared.
